Michael Mayer

658 total citations
15 papers, 457 citations indexed

About

Michael Mayer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Michael Mayer has authored 15 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 2 papers in Surgery. Recurrent topics in Michael Mayer's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Michael Mayer is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Michael Mayer collaborates with scholars based in Switzerland, United States and Austria. Michael Mayer's co-authors include Herbert Lochs, Rainer Hoffmann, Dieter Genser, Wolfgang E. Fleig, Preben Bo Mortensen, Wolfgang Petritsch, Péter Bauer, Michael Staun, L. B. Nesje and Mathias Plauth and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Lancet Oncology.

In The Last Decade

Michael Mayer

15 papers receiving 442 citations

Peers

Countries citing papers authored by Michael Mayer

Since Specialization

Citations

This map shows the geographic impact of Michael Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Mayer more than expected).

Fields of papers citing papers by Michael Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Mayer. The network helps show where Michael Mayer may publish in the future.

Co-authorship network of co-authors of Michael Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Mayer. A scholar is included among the top collaborators of Michael Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Mayer. Michael Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) 2012 ·Lung Cancer ·Francesco Zappa, (unknown), Daniel Betticher, Roger von Moos, Lukas Bubendorf, Adrian F. Ochsenbein, Oliver Gautschi, Elisabeth Oppliger Leibundgut, Patrizia Froesch, Rolf A. Stahel, Thomas Heß, Daniel Rauch, (unknown), Michael Mayer, Susanne Crowe, Peter Brauchli, Karin Ribi, Miklos Pless	27
2	Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03) 2011 ·European Journal of Cancer ·Gianfranco Pesce, Dirk Klingbiel, Karin Ribi, (unknown), Roger von Moos, Marc Schlaeppi, Clemens B. Caspar, Natalie Fischer, Sandro Anchisi, Solange Peters, Richard Cathomas, Jürg Bernhard, (unknown), Giannicola DʼAddario, (unknown), Damien C. Weber, Stephan Bodis, Miklos Pless, Michael Mayer, Roger Stupp	63
3	Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial, SAKK 19/05. 2011 ·Journal of Clinical Oncology ·Francesco Zappa, (unknown), Daniel Betticher, Roger von Moos, Martin Brutsche, Florent Baty, Lukas Bubendorf, Adrian F. Ochsenbein, Elisabeth Oppliger Leibundgut, Oliver Gautschi, Patrizia Froesch, R. Stahel, Daniel Rauch, Peter Schmid, Michael Mayer, S. Crowe, Peter Brauchli, Karin Ribi, Miklos Pless	2
4	Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06) 2010 ·Annals of Oncology ·Christoph Rochlitz, Thomas Ruhstaller, (unknown), Christian Spirig, Jens Huober, Thomas Suter, Monika Bühlmann, (unknown), (unknown), Roger von Moos, Sun Young Rha, Daniel Rauch, Andreas Müller, (unknown), Richard Herrmann, (unknown), Michael Mayer, Khalil Zaman	21
5	A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials 2009 ·Contemporary Clinical Trials ·Jan C. Schuller, Michael Mayer, Doris Lanz, Shu‐Fang Hsu Schmitz, Peter Brauchli, Nicolas Leupin	2
6	Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial 2009 ·The Lancet Oncology ·Roger Stupp, Michael Mayer, Roger Kann, Walter Weder, (unknown), Daniel Betticher, Arnaud Roth, Rolf A. Stahel, Sabine Balmer Majno, Solange Peters, Lorenz Jost, Markus Furrer, Sandra Thierstein, Ralph A. Schmid, (unknown), René-Olivier Mirimanoff, Hans-Beat Ris, Miklos Pless	87
7	9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKK 2009 ·European Journal of Cancer Supplements ·Francesco Zappa, (unknown), Daniel Betticher, Roger von Moos, Adrian F. Ochsenbein, R. Stahel, Daniel Rauch, Peter Schmid, Michael Mayer, Miklos Pless	2
8	Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 2007 ·Annals of Oncology ·G. D’Addario, Daniel Rauch, Roger Stupp, Miklos Pless, R. Stahel, Nicolas Mach, L.M. Jost, (unknown), C. Tapia, Michel Bihl, Michael Mayer, Karin Ribi, (unknown), Lukas Bubendorf, Daniel Betticher	34
9	Preoperative chemoradiotherapy in non-small cell lung cancer (NSCLC) patients with operable stage IIIB disease. A phase II trial of the Swiss Group for Clinical Cancer Research (SAKK) 2007 ·Journal of Clinical Oncology ·Miklos Pless, Roger Stupp, (unknown), (unknown), Michael Mayer, Sandra Thierstein, R. Stahel, Daniel Betticher, Sabine Balmer Majno, Hans‐Beat Ris	1
10	Stability of Cisplatin, Doxorubicin, and Mitomycin Combined with Ioversol for Chemoembolization 2001 ·Annals of Pharmacotherapy ·Michael Mayer, (unknown), Dominic A. Solimando, (unknown), (unknown), Gregory Fant	5
11	Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI 2000 ·Gastroenterology ·Herbert Lochs, Michael Mayer, Wolfgang E. Fleig, Preben Bo Mortensen, Péter Bauer, Dieter Genser, Wolfgang Petritsch, Martin Raithel, Rainer Hoffmann, (unknown), Mathias Plauth, Michael Staun, L. B. Nesje	198
12	Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer 2000 ·Hospital Pharmacy ·Michael Mayer, Dominic A. Solimando, J. Aubrey Waddell	2
13	[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer]. 1990 ·PubMed ·Franck Chauvin, (unknown), Christine Lasset, G. Catimel, Michael Mayer, (unknown), (unknown), (unknown), M. Clavel	10
14	Bile levels of imipenem following different dose regimens. 1985 ·PubMed ·Michael Mayer, (unknown), W. Opferkuch	2
15	[Regional chemotherapy by intra-arterial route in the treatment of advanced-stage pelvic cancers]. 1962 ·PubMed ·J Colon, Michael Mayer, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact